Glipatab 25 mg Tablet contains Empagliflozin, an SGLT2 inhibitor that works by preventing glucose reabsorption in the kidneys, thereby increasing glucose excretion in urine and lowering blood glucose levels. It is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.